Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Inhibition of TNF-alpha - a therapeutic alternative for chronic treatment resistant ocular inflammation

Nölle B.
Univ.-Klinikum Schleswig-Holstein, Campus Kiel

TNFa is a cytokine mediator of inflammation with important proinflammatory role in ocular inflammation. Blockade of TNF-alpha receptors with either the monoclonal antibody infliximab or etanercept is meanwhile a clinical routine procedure. These substances are accepted and admitted for treatment of chronic polyarthritis, juvenile chronic arthritis, psoriatric arthritis, and Crohn`s disease in cases of resistance/ineffectivity to routine immunosuppression or relevant contraindications. Reports of various applications of these substances in ocular inflammation confirm a rapid, mostly dramatic suppression of inflammation. However, these beneficial effects are often transitory. At present the ocular indications or contraindications are not clear cut evident. In addition, dosage and time of treatment can be optimized. There are no controlled studies available. However, if known contraindications are accepted (active microbial infection, especially tuberculosis, vaccination with living vaccine, severe heart insufficiency, hypersensitivity to mouse proteins, active multiple sclerosis, uncontrolled diabetes mellitus) the number and intensity of side effects is limited and acceptable. Cases with treatment resistant inflammation due to orbital granulomas in Wegener granulomatosis, rheumatic keratomalacia in chronic polyarthritis or in Sjögrens syndrome, acute anterior uveitis in Bechterew disease showed improvement with TNF-alpha blockade. At p


Zurück | Back